Despite improvements in modern cardiovascular therapy, the morbidity and mortality of
ischaemic heart disease (IHD) and heart failure (HF) remain significant in Europe and …

This paper aims to provide an important update on the recent preclinical and clinical trials
using cell therapy strategies and engineered heart tissues for the treatment of postinfarction …

Background: The adult mammalian heart has limited regenerative capacity, mostly
attributable to postnatal cardiomyocyte cell cycle arrest. In the last 2 decades, numerous …

MicroRNA-based therapies that target cardiomyocyte proliferation have great potential for
the treatment of myocardial infarction. In previous work, we showed that the miR-302/367 …

Rationale: The effectiveness of transplanted, human induced pluripotent stem cell–derived
cardiomyocytes (hiPSC-CMs) for treatment of ischemic myocardial injury is limited by the …

The adult mammalian heart is thought to be a terminally differentiated organ given the
postmitotic nature of cardiomyocytes. Consequently, the potential for cardiac repair through …

Understanding how macrophages promote myocardial repair can help create new therapies
for infarct repair. We aimed to determine what mechanisms underlie the reparative …

Rationale: New strategies in the field of cardiac regeneration are directed at identifying
proliferation-inducing substances to induce regrowth of myocardium. Current screening …

During the postnatal period in mammals, the heart undergoes significant remodeling and
cardiac cells progressively lose their embryonic characteristics. At the same time, notable …

Endogenous capability of the post-mitotic human heart holds great promise to restore the
injured myocardium. Recent evidence indicates that the extracellular vesicles (EVs) regulate …